23351-1-AP

antibody from Proteintech Group

Targeting: AMOTL2 LCCP

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Antibody Data

Product number

23351-1-AP

Provider

Proteintech Group

Product name

AMOTL2 antibody

Antibody type

Polyclonal

Description

KD/KO validated AMOTL2 antibody (Cat. #23351-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

E3 ubiquitin ligase ITCH-mediated proteasomal degradation of WBP2 sensitizes breast cancer cells to chemotherapy through restraining AMOTL2/c-JUN axis.

Zhu M, Zhong W, Wong S, Luo X, Hong Z, Lin J, Wu J, Zhou Y, Qi Z, Chen S
Biochemical pharmacology 2025 Feb;232:116720

---

Tankyrase inhibition interferes with junction remodeling, induces leakiness, and disturbs YAP1/TAZ signaling in the endothelium.

Ma N, Wibowo YC, Wirtz P, Baltus D, Wieland T, Jansen S
Naunyn-Schmiedeberg's archives of pharmacology 2024 Mar;397(3):1763-1789

---

The circadian gene ARNTL2 promotes nasopharyngeal carcinoma invasiveness and metastasis through suppressing AMOTL2-LATS-YAP pathway.

Zou W, Lei Y, Ding C, Xiao H, Wang S, Liang S, Luo W, Long Z, He S, Li Q, Qiao H, Liu N, Mao Y
Cell death & disease 2024 Jul 2;15(7):466

---

Restoring mechanophenotype reverts malignant properties of ECM-enriched vocal fold cancer.

Kaivola J, Punovuori K, Chastney MR, Miroshnikova YA, Abdo H, Bertillot F, Krautgasser F, Franco JD, Conway JRW, Follain G, Hagström J, Mäkitie A, Irjala H, Ventelä S, Hamidi H, Scita G, Cerbino R, Wickström SA, Ivaska J
bioRxiv : the preprint server for biology 2024 Aug 23;

---

FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis.

Pan S, Zhu J, Liu P, Wei Q, Zhang S, An W, Tong Y, Cheng Z, Liu F
Theranostics 2023;13(14):5130-5150

---

Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma.

Evsen L, Morris PJ, Thomas CJ, Ceribelli M
Pharmaceuticals (Basel, Switzerland) 2023 Nov 21;16(12)

---

Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway.

Du Y, Cui R, Tian N, Chen M, Zhang XL, Dai SM
Arthritis research & therapy 2022 Aug 8;24(1):188

---

MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis.

Kantar D, Mur EB, Mancini M, Slaninova V, Salah YB, Costa L, Forest E, Lassus P, Géminard C, Boissière-Michot F, Orsetti B, Theillet C, Colinge J, Benistant C, Maraver A, Heron-Milhavet L, Djiane A
Scientific reports 2021 Mar 11;11(1):5752

---

Hsa_circ_0024093 accelerates VSMC proliferation via miR-4677-3p/miR-889-3p/USP9X/YAP1 axis in in vitro model of lower extremity ASO.

Zhang X, Wang P, Yuan K, Li M, Shen Y, Que H, Wang Y, Liang W
Molecular therapy. Nucleic acids 2021 Dec 3;26:511-522

---

AMOT130 drives BMP-SMAD signaling at the apical membrane in polarized cells.

Brunner P, Hastar N, Kaehler C, Burdzinski W, Jatzlau J, Knaus P
Molecular biology of the cell 2020 Jan 15;31(2):118-130

---

Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer.

Guo Z, Wang X, Yang Y, Chen W, Zhang K, Teng B, Huang C, Zhao Q, Qiu Z
Molecular therapy. Nucleic acids 2020 Aug 25;22:179-195